DLA Piper advises Arlington Capital Partners in CBSET majority growth investment

DLA Piper guided Arlington Capital Partners, a private investment firm focused on government regulated industries, in its majority growth investment in Concord Biomedical Sciences and Emerging Technologies, Inc. (CBSET), a provider of translational research and product development services.

CBSET offers a range of preclinical research and testing services, as well as regulatory support for both FDA and global submissions for the medical device, pharmaceutical, diagnostic, and biomedical research industries.

“We are honored to have collaborated with Arlington Capital Partners on this significant growth investment in CBSET,” said Private Equity Vice Chair and Partner Eric Grossman, who co-led DLA Piper’s deal team. “This transaction demonstrates DLA Piper’s ability to provide integrated, cross-practice counsel to our clients on complex transactions. We appreciate the trust Arlington placed in our team and look forward to supporting their continued success.”

In addition to Grossman (Reston), Of Counsel Melissa Sampson (Washington, DC) co-led the firm’s multi-practice team, with support from Partners Greg Saiontz (Washington, DC), Matt Servies (Atlanta), Robert J. O’Connor (Boston), Sue Zabloudil (Miami), and Associate Michelle Bauer (Washington, DC).

With more than 225 global lawyers who provide strategic counsel to private equity funds and their industry-leading portfolio companies, DLA Piper’s Private Equity practice has the capacity, experience and relationships to help drive value across the investment life cycle by delivering responsive, efficient, and integrated solutions around the world. The Private Equity practice is also the #2 most active law firm globally by PitchBook.